Incipient neuroleptic malignant syndrome with quetiapine/paroxetine combination treatment: Atypical presentation and early, successful rechallenge with olanzapine

International Journal of Psychiatry in Clinical Practice

Volumn 9, Issue 4, 2005, Pages 296-298

  Grignon, Sylvain ^a,b   Brethes, Jean Ianic ^a   Chamberland, Martine ^a   Guimaraes, Daniel B ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Creatine kinase; Neuroleptic malignant syndrome; Olanzapine; Paroxetine; Quetiapine

Indexed keywords

CREATINE KINASE; LORAZEPAM; LOXAPINE; MYOGLOBIN; OLANZAPINE; PAROXETINE; QUETIAPINE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTICLE; CASE REPORT; CATATONIA; ENZYME BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEVER; HUMAN; HYDRATION; HYPERTENSION; MALE; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SCHIZOPHRENIA; TACHYCARDIA;

EID: 27844585904     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500510029110     Document Type: Article

References (19)

1. Velamoor VR, Norman RM, Caroff SN, et al. Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 1994;182:168-73.
2. Young C. A case of neuroleptic malignant syndrome and serotonin disturbance. J Clin Psychopharmacol 1997;17:65-6.
3. Heinemann F, Assion HJ, Hermes G, et al. Paroxetine-induced neuroleptic malignant syndrome]. Nervenarzt 1997;68:664-6.
4. Kontaxakis VP, Havaki-Kontaxaki BJ, Pappa DA, et al. Neuroleptic malignant syndrome after addition of paroxetine to olanzapine. J Clin Psychopharmacol 2003;23:671-2.
5. Ananth J, Parameswaran S, Gunatilake S, et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
6. Bourgeois JA, Babine S, Meyerovich M, et al. A case of neuroleptic malignant syndrome with quetiapine. J Neuropsychiatry Clin Neurosci 2002;14:87.
7. Solomons K. Quetiapine and neuroleptic malignant syndrome. Can J Psychiatry 2002;47:791.
8. Bora E, Saffet Gonul A, Akdeniz F, et al. Neuroleptic malignant-like syndrome induced with low-dose quetiapine treated with electroconvulsive therapy. Eur Psychiatry 2003;18:323.
9. Boot E, De Haan L. Massive increase in serum creatine kinase during olanzapine and quetiapine treatment, not during treatment with clozapine. Psychopharmacology (Berlin) 2000;150:347-8.
10. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
11. Arvanitis LA, Miller BG. Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-46.
12. Arango C, Bobes J. Managing acute exacerbations of schizophrenia: Focus on quetiapine. Curr Med Res Opin 2004;20:619-26.
13. Hermesh H, Manor I, Shiloh R, et al. High serum creatinine kinase level: Possible risk factor for neuroleptic malignant syndrome. J Clin Psychopharmacol 2002;22:252-6.
14. Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001;251(Suppl 1):18-3.
15. Northoff G, Wenke J, Pflug B. Increase of serum creatine phosphokinase in catatonia: An investigation in 32 acute catatonic patients. Psychol Med 1996;26:547-53.
16. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996;15:395-405.
17. Kubo S, Orihara Y, Kitamura O, et al. An autopsy case of neuroleptic malignant syndrome (NMS) and its immunohistochemical findings of muscle-associated proteins and mitochondria. Forensic Sci Int 2001;115:155-8.
18. Modica-Napolitano JS, Lagace CJ, Brennan WA, et al. Differential effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch Pharm Res 2003;26:951-9.
19. Gefvert O, Lundberg T, Wieselgren IM, et al. D(2) and 5HT(2a) receptor occupancy of different doses of quetiapine in schizophrenia: A PET study. Eur Neuropsychopharmacol 2001;11:105-10.